Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.49 |
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4542082 | 0.84 | NAMPT (0.54) | NAMPTHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL8863056 | 0.80 | CA1 (0.65) | HSP90AA1CXCR5APLNRCCR6HTR6 | |
| SCHEMBL30859041 | 0.80 | CA1 (0.65) | HSP90AA1CXCR5APLNRCCR6HTR6 | |
| SCHEMBL4538358 | 0.80 | HTR6 (0.50) | NAMPTHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL4537377 | 0.80 | NAMPT (0.50) | NAMPTHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL15530364 | 0.80 | NAMPT (0.49) | NAMPTHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL4538568 | 0.80 | HTR6 (0.49) | NAMPTHSP90AA1CXCR5APLNRCCR6 | |
| SCHEMBL15689403 | 0.79 | HSP90AA1 (0.53) | NAMPTHSP90AA1CXCR5APLNRCCR6 | |
| Hydrochloric Acid SCHEMBL11261755 | 0.78 | CA1 (0.62) | HSP90AA1CXCR5APLNRCCR6HTR6 | |
| SCHEMBL15231950 | 0.77 | LOXL2 (0.53) | NAMPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2820017-B1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | GENENTECH INC (US) | 2016-12-21 | — | — | EP | claimed |
| EP-2820017-B1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | GENENTECH INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355514-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | VALO EARLY DISCOVERY, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9458172-B2 | Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives | VALO HEALTH, INC. | 2016-10-04 | — | — | US | disclosed |
| US-20150175621-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | Valo Health, LLC | 2015-06-25 | — | — | US | disclosed |
| WO-2013170191-A1 | METHODS OF USING ANTAGONISTS OF NAD BIOSYNTHESIS FROM NICOTINAMIDE | GENENTECH, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355514-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | TPMT, TYMS, TYMP | NAMPT 82/4885HSP90AA1 2618/4885CXCR5 3061/4885 |
| US-20150175621-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | TPMT, TYMS, TYMP | NAMPT 82/4885HSP90AA1 2618/4885CXCR5 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.